The University of Oklahoma Health Sciences Center
Stephenson Cancer Center
975 NE 10th St, BRC 417B
Oklahoma City, OK 73104
Education:
- MS - Biochemistry, University of Calcutta, India (1987)
- PhD - Biochemistry, University of Calcutta, India (1998)
Fellowship:
- Research Fellow - Department of Microbiology, Bose Institute, Calcutta, India (1989-1997)
- Post-Doctoral Fellow - Department of Pathology, St. Louis University, St. Louis, MO (1998-1999)
- Research Associate - Department of Pathology, St. Louis University, St. Louis, MO (1999-2001)
- Research Associate - Division of Hematology, Mayo Clinic, Rochester, MN (2006-2008)
Clinical/Research Interests:
- Chronic Lymphocytic Leukemia (CLL) cell biology
- Tyrosine Kinase (RTK & non-RTK) signaling
- Cell Survival Signaling Pathways
- Drug Targeting
- Small Molecule Inhibitors
- B Cell Lymphomas
- Tumor Microenvironment/Extracellular
- Vesicles
Funding:
R21CA274072 Asish Ghosh (PI) 7/7/2022 – 6/30/2025 (NCE)
NIH/NCI
Study Pro-oncogenic Role of BCL6 in CLL Tumorigenesis.
The proposed studies have potential to establish a new prognostic parameter and therapeutic avenue via targeting BCL6 in CLL cells in combination with the current BCR-targeted therapy, ibrutinib. Tumorigenesis.
Role: PI
R21CA274072 Asish Ghosh (PI) 4/10/2023 – 3/31/2025
NIH/NCI
Pro-Oncogenic Role of Mitochondrial Lipid Kinase in CLL.
The proposed studies have enormous potential to establish a new prognostic parameter and therapeutic avenue via targeting AGK in CLL cells with or without the current BCR-targeted therapy, ibrutinib.
Role: PI
Select Honors and Accomplishments:
- Fellowships from the Council of Scientific and Industrial Research (CSIR), Government of India
- Young Investigator Award, Mayo Clinic Angiogenesis Symposium (2008)
- Hematology Research Summit Award Recipient, Mayo Clinic (2012)
Select Publications:
- Mamidi MK, et al. Idelalisib activates AKT via increased recruitment of PI3Kdelta/PI3Kbeta to BCR signalosome while reducing PDK1 in post-therapy CLL cells. Leukemia. 2022. Epub 20220514. doi: 10.1038/s41375-022-01595-0. PubMed PMID: 35568768.
- Maiti GP, et al. SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. Blood Cancer J. 2021;11(5):93. Epub 2021/05/19. doi: 10.1038/s41408-021-00484-6. PubMed PMID: 34001853; PMCID: PMC8129117.
- Sinha S, et al. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015;21(9):2115-26. Epub 2015/02/13. doi: 10.1158/1078-0432.CCR-14-1892. PubMed PMID: 25673699.